Maze Therapeutics Appoints Misbah Tahir As Chief Financial Officer, Bringing 20+ Years Of Biopharma Financial Leadership Including $1 Billion In Fundraising Success At IGM Biosciences

Maze Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing precision small molecule medicines for patients with kidney and metabolic diseases, has announced the appointment of Misbah Tahir as its Chief Financial Officer, effective immediately. Tahir brings with him more than two decades of experience in financial and strategic leadership within the biopharmaceutical industry. He most recently served as Chief Financial Officer at IGM Biosciences, Inc., where he played a pivotal role in guiding the company through its 2019 initial public offering and collaborated with the executive team to raise over $1 billion through multiple equity financings and a pharma partnership.

Jason Coloma, Ph.D., chief executive officer of Maze, mentioned, “We’re thrilled to welcome Misbah as Maze’s Chief Financial Officer at such a pivotal time for the company. We are preparing for several key milestones, including data for MZE782 in phenylketonuria and chronic kidney disease in Q3 2025 and initial data from our Phase 2 HORIZON trial of MZE829 in APOL1-mediated kidney disease in Q1 2026. Misbah’s proven track record in scaling biotech companies, combined with deep financial and operational expertise, will be instrumental in driving our growth strategy as we maintain our focus on clinical execution.”

Mr. Tahir, stated, “Maze’s strong balance sheet and expected cash runway into 2H 2027, combined with its differentiated precision genetics platform, advancing clinical pipeline, and disciplined development approach have given the company the opportunity to create significant value for both patients and shareholders. I look forward to partnering with Jason and the entire leadership team to drive the next phase for Maze as we work together to harness the power of human genetics to develop potentially novel, small molecule precision medicines for patients with kidney and metabolic diseases.”

Prior to his time at IGM, he held senior finance positions at Dermira, Inc., which was acquired by Eli Lilly and Company; Onyx Pharmaceuticals, Inc., which was acquired by Amgen Inc.; and Human Genome Sciences Inc., later acquired by GSK plc. In these roles, he contributed significantly to capital formation, strategic partnerships with pharmaceutical companies, and the successful launch of products.

Tahir began his career in the biopharmaceutical sector at Amgen, Inc. after working as a management consultant with Oliver Wyman. He holds a Master of Business Administration degree from the University of Michigan Business School and a Bachelor of Arts degree in International Relations from the University of Pennsylvania.